Skip to Content

Ofev Approval History

  • FDA approved: Yes (First approved October 15th, 2014)
  • Brand name: Ofev
  • Generic name: nintedanib
  • Dosage form: Capsules
  • Company: Boehringer Ingelheim Pharmaceuticals, Inc.
  • Treatment for: Idiopathic Pulmonary Fibrosis

Ofev (nintedanib) is a small molecule tyrosine kinase inhibitor (TKI) for the treatment of idiopathic pulmonary fibrosis.

Development History and FDA Approval Process for Ofev

DateArticle
Oct 15, 2014Approval FDA Approves Ofev (nintedanib) for Idiopathic Pulmonary Fibrosis
Jul 16, 2014Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Jul  2, 2014U.S. FDA Accepts NDA Filing for Boehringer Ingelheim’s Nintedanib for Idiopathic Pulmonary Fibrosis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide